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Table 1
Results for Aplasia and HCT after Clofarabine Salvage
Number (%)
Patients
Number (%) Alive
(thru 10/1/12)
Patients Receiving Clofarabine 15 (100%) 6 (40%)
+Aplasia 9 (60%) 5 (33%)
+Aplasia, -AML 5 4 (27%)
+Aplasia , +AML 4 1 (7%)
-Aplasia 6 (40%) 1 (7%)
-Aplasia, -AML 2 1 (7%)
-Aplasia, +AML 4 0 (0%)
Number (%) Alive
after HCT
Patients receiving HCT 10 (67%) 6 (60%) *
+Aplasia 8 5 (50%)
+Aplasia, -AML 6 4
+Aplasia, +AML 2 1 y
-Aplasia 2 1 (10%)
-Aplasia, -AML 2
-Aplasia, +AML 0 0
* range day 100-365
y 11 months post HCT
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describe the incidence of fungal infection, VOD incidence and
relapse free survival after HCT was evaluated.
Patients/Methods: 15 patients with refractory AML received
clofarabine between January 1, 2011 and June 30, 2012.
Retrospective chart review was performed for demographic
data, disease characteristics, pathology results and outcomes
data. Speciﬁc data on fungal disease, ability to achieve
aplastic bone marrow (deﬁned as <10% cellularity approxi-
mately 14 days after treatment), subsequent treatment with
HCT and mortality data after treatment were collected.
Results: See Table 1. Clofarabinewas given alone (8 patients),
or in combination with other agents: clofarabine plus cytar-
abine (5 patients) and clofarabine, cytarabine and ﬁlgrastim
(2 patients). 2 (13%) patients developed new fungal infection
after clofarabine and there was no incidence of VOD.
Conclusion: Patients with refractory AML have a dismal
prognosis and better treatment options are needed. This
study conﬁrms prior reports that clofarabine is active in
refractory AML and can be used as a cytoreductive bridge to
HCT in aplasia. 40% of patients with refractory AML treated
with clofarabine in this study are alive (range, day 100 to
365) without evidence of disease after HCT. No increase in
fungal infections was noted after clofarabine and no post HCT
VOD observed. These results show favorable outcomes for
patients with refractory AML given clofarabine salvage with
subsequent HCT in aplasia. Future studies comparing clo-
farabine to other salvage regimens in refractory AML and
analysis of cost efﬁcacy are warranted.236
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DNA alkylating agent busulfan (Bu) and nucleoside
analogs clofarabine (Clo) and ﬂudarabine (Flu) are commonlyused as part of the pre-transplant conditioning regimen in
allogeneic hematopoietic stem cell transplantation (allo-
HSCT). We previously reported that a combination of
[Bu+Clo+Flu] has a synergistic cytotoxicity in AML cells. We
hypothesized that combination of [Bu+Clo+Flu] with histone
deacetylase inhibitor SAHA will further enhance the cyto-
toxicity. We exposed the AML cell lines KBM3/Bu2506 (KBu)
to Bu (10 mg/ml), Clo (10 nM), Flu (0.2 mM) and SAHA (0.7
mM), and OCI-AML3 to Bu (1.5 mg/ml), Clo (10 nM), Flu (0.5
mM) and SAHA (0.7 mM) alone or in various combinations.
Exposure of these cells to Bu, Clo, Flu or SAHA alone, or to
two-drug combinations [Bu+Clo], [Bu+Flu] and [Clo+Flu], did
not signiﬁcantly affect cell proliferation relative to the
control. The combination of [Bu+Clo+Flu] resulted in 20-30%
inhibition of cell proliferation. Addition of SAHA to the
[Bu+Clo+Flu] mixture further enhanced the inhibition of
proliferation of KBu and OCI-AML3 by 60% and 80%, respec-
tively, suggesting synergistic cytotoxicity. Biochemical anal-
yses suggest that this cytotoxicity may be attributed to (1)
activated DNA-damage response and cell cycle checkpoint
through ATM-CHK2-P53 pathway, (2) histone 3 and histone
4 modiﬁcations, and (3) activation of both the intrinsic and
extrinsic pathways of apoptosis. The pro-apoptotic proteins
BAX and cleaved BID increased in the mitochondria when
cells were exposed to [Bu+Clo+Flu+SAHA], and further the
pro-survival protein MCL-1 was cleaved and yielded a pro-
apoptotic 28-kDa protein, while the level of the pro-survival
protein BCL-xL decreased. Finally, phosphorylated and pan
P53 increased in themitochondria when OCI-AML3 cells that
harbor wild type P53 were exposed to [Bu+Clo+Flu] or
[Bu+Clo+Flu+SAHA]. These changes in the level of proteins
involved in mitochondrial control of apoptosis may conse-
quently cause mitochondrial outer membrane per-
meabilization (MOMP). The mitochondrial membrane
potential, as a marker for MOMP, decreased by 40% or 80%
when cells were exposed to [Bu+Clo+Flu] or [Bu+Clo+-
Flu+SAHA], respectively, and this change caused leakage of
cytochrome cand SMAC/DIABLO into the cytosol leading to
caspase activation, and release of apoptosis-inducing factor
(AIF) into the nucleus, inducing nuclear fragmentation and
cell death. These results provide a mechanistic basis for
introducing SAHA as a complement to our double nucleo-
side-busulfan combination in pre-transplant conditioning
therapy for AML patients undergoing allo-HSCT. We
hypothesize that SAHA-associated enhancement of
apoptosis will result in increased antitumor efﬁcacy with
retained safety in a clinical transplant program.237
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Background: After performing thousands of bone marrow
biopsies (BMX), our nurse lead biopsy staff started identi-
fying what is likely intuitively known about speciﬁc diseases
and their BMX characteristics. We began collecting data both
on core lengths and hemodilution rates to see if our data
validates our suspicions that patients with plasma cell
dyscrasias (PCD) have signiﬁcantly smaller core lengths and
